Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, phase II study to evaluate the clinical activity of
pembrolizumab in combination with pazopanib compared to pazopanib monotherapy.